Vascular disrupting agents.
作者： John W. Lippert
DOI: 10.1016/J.BMC.2006.10.020
关键词: ZD6126 、 Pharmacology 、 Chemistry 、 Vascular structure 、 Cancer treatment 、 Cancer 、 Solid tumor
摘要: A clear definition for vascular targeting agents (VTAs) and vascular disrupting agents (VDAs) has separated the two as distinct methods of cancer treatment. VDAs differ from VTAs (…
elsevier.com
sci-hub.se 参考文章(113)
S. D. Shnyder, George Pettit, P. A. Cooper, J. W. Lippert, M. C. Bibby, Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Research. ,vol. 23, pp. 1619- 1623 ,(2003)
Suga Y, Ohsumi K, Nihei Y, Tsuji T, Nakagawa R, Akiyama Y, Hatanaka T, Fukuda Y, Morinaga Y, Ohishi K, Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anti-cancer Drug Design. ,vol. 14, pp. 539- ,(1999)
George Pettit, P. A. Cooper, S. E. Holwell, J. W. Lippert, M. J. Thompson, M. C. Bibby, S. W. Martin, Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Research. ,vol. 22, pp. 3933- 3940 ,(2002)
S. A. Hill, S. J. Lonergan, J. Denekamp, D. J. Chaplin, The effect of vinca alkaloids on tumour blood flow. Advances in Experimental Medicine and Biology. ,vol. 345, pp. 417- 422 ,(1994) , 10.1007/978-1-4615-2468-7_55
Kazuo Kubota, Katsuyoshi Hori, Yasufumi Sato, Sachiko Saito, Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Medical Science Monitor. ,vol. 7, pp. 26- 33 ,(2001)
George Pettit, D. J. Swaine, P. M. Loadman, K. Grosios, M. C. Bibby, Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Research. ,vol. 20, pp. 229- 233 ,(2000)
Jagat R. Kanwar, Rupinder K. Kanwar, Geoffrey W. Krissansen, Sushil Pandey, Lai-Ming Ching, Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Research. ,vol. 61, pp. 1948- 1956 ,(2001)
S. D. Shnyder, G. R Pettit, P. A. Cooper, K. Grosios, S. E. Holwell, J. W. Lippert, M. C. Bibby, Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Research. ,vol. 22, pp. 707- 711 ,(2002)
Anticancer Agents from Natural Products CRC Press. ,(2005) , 10.1201/9781420039658
R. B. Pedley, J. A. Boden, R. Boden, A. A. Flynn, P. A. Keep, R. H. J. Begent, G. M. Boxer, Ablation of Colorectal Xenografts with Combined Radioimmunotherapy and Tumor Blood Flow-modifying Agents Cancer Research. ,vol. 56, pp. 3293- 3300 ,(1996)